Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

导出 OA

翻译打印收藏纠错

第一作者： Nina,Zila

第一单位： 1Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

作者： Nina,Zila ^[1] ; Andrea,Bileck ^[2] ; Besnik,Muqaku ^[3] ; Lukas,Janker ^[2] ; Ossia M,Eichhoff ^[2] ; Phil F,Cheng ^[2] ; Reinhard,Dummer ^[4] ; Mitchell P,Levesque ^[4] ; Christopher,Gerner ^[4] ; Verena,Paulitschke ^[4]

作者单位： 1Department of Dermatology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. ^[1] 2Department of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria. ^[2] 3University of Applied Sciences (FH Campus Wien), Vienna, Austria. ^[3] Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland. ^[4]

关键词 BRAF mutation Cerebral melanoma metastases Drug resistance MAP kinase inhibitor Melanoma Proteomics

DOI 10.1186/s12014-018-9189-x

PMID 29541007

发布时间 2024-03-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical proteomics

2018年15卷

13页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Clinical proteomics

相似文献

Clinical proteomics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.

Clinical proteomics

相似文献

Clinical proteomics

相关期刊

检索历史清除